Company intelligence / Profile preview

MAP Pharmaceuticals

Mountain View, California, United Statesmap.org ↗

Ownership: Private
Development stage: Other

Overview

MAP Pharmaceuticals developed LEVADEX, an orally inhaled formulation of dihydroergotamine for acute migraine treatment in adults. The product was under FDA review at the time of Allergan’s acquisition. The company leveraged proprietary particle engineering and inhalation technologies to improve efficacy and side effect profiles for neurological drugs. Clinical results showed promise but faced regulatory delays due to manufacturing and device issues.

Therapeutic areas: Neurology
Modalities: Small moleculeDevice (inhalation drug delivery)
Industry: Biotech

Partnerships

Allergan (co-promotion agreement prior to full acquisition)

Beyond the preview

Go deeper on MAP Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAP Pharmaceuticals.

Explore the full profile